AD

Aster DM Quality Care Ltd

Q2 FY27Healthcare Services

Aster DM Quality Care Q2 Results 2026 (FY27) investor presentation: Revenue & Margins

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹2,829Cr
Net profit
₹322Cr
Margin
23.4%

Based on Aster DM Quality Care Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹713
Market cap₹62.2K Cr
P/E172.3

The short version

Q2 FY27 revenue: INR 2,829 Cr, up 19% YoY from INR 2,382 Cr in Q2 FY26 (Page 6, 9, 10). Q2 FY27 Operating EBITDA: INR 678 Cr, up 25% YoY from INR 545 Cr (Page 17, 9).

From Aster DM Quality Care Ltd's Q2 FY27 earnings-call transcript · updated 6 Nov 2026.

How did Aster DM Quality Care's revenue grow in the September 2026 quarter?

  • Q2 FY27 revenue: INR 2,829 Cr, up 19% YoY from INR 2,382 Cr in Q2 FY26 (Page 6, 9, 10).
  • Q2 FY27 patient volumes: 2.18 million, up 12% YoY from 1.95 million in Q2 FY26 (Page 9).
  • Operational beds increased 4% YoY to 10,611 in Q2 FY27 (Page 9).
  • Revenue growth driven by 12% patient volume growth and 4% growth in operational beds (Page 9).
  • CONGO specialty revenue grew 16-19% YoY, contributing 53-54% to overall revenue (Page 15, 26).

2 more points from Aster DM Quality Care Ltd's call on revenue

Create a free account to keep reading this call

What happened to Aster DM Quality Care's margins in Q2 FY27?

See what Aster DM Quality Care Ltd said on profitability & margins — free account, 30 seconds.

What capex is Aster DM Quality Care planning?

  • Building a 15,000+ bed healthcare network; adding 4,230 beds to reach 15,070 total beds (Page 18).
  • Planned bed additions by region (Page 27 & 28):
  • Kerala & Tamil Nadu: 1,179 beds
  • South-West & Central (Karnataka, Maharashtra, Madhya Pradesh, Chhattisgarh): 1,941 beds
  • South-East (Andhra Pradesh, Telangana, Odisha, Bangladesh): 1,110 beds
  • INR 1,200+ Cr capex invested including project capex, growth capex, and refresh over last 18 months (Page 11).
  • Addition of medical technology assets in Q2 FY27: 1 LINAC, 1 Digital PET-CT, 3 robots, 2 cath labs, 1 MRI (Page 10).
  • Commissioned a new 32-bed CARE Cancer Institute in Raipur, expanding advanced cancer care (Page 10).
  • Planned bed capacity growth staged across FY27 to FY30 & beyond (Page 18):
  • FY27: Addition of ~760 beds
  • FY28: Addition of ~570 beds

2 more points from Aster DM Quality Care Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Aster DM Quality Care raising money or cutting debt?

See what Aster DM Quality Care Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Aster DM Quality Care's order book?

See what Aster DM Quality Care Ltd said on order book & pipeline — free account, 30 seconds.

Aster DM Quality Care Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Aster DM Quality Care Ltd Q2 FY27 results — key figures

Aster DM Quality Care Ltd Q2 FY27 reported results vs year-ago quarter, ₹ crore
₹ CrQ2 FY27
Revenue2,829
Operating profit (EBITDA)663
Operating margin23.4%
Profit before tax427
Net profit (PAT)322
EPS (₹)3.19

Source: Aster DM Quality Care Ltd's results filing to NSE (consolidated), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.8K Cr, net profit ₹322 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Nidan Laboratories & Healthcare (Q2 FY27)

    Operating Margin: Not explicitly stated as a percentage; however, total income from operations is Rs 1,201.76 lakhs, so approximate operating margin = (EBITDA…

  • Suven Life Sciences (Q2 FY27)

    91.92 lakhs for the quarter ended September 30, 2025, indicating a revenue increase of approximately 30.3%. Key results statement takeaways from Suven Life Scie

  • Fortis Healthcare (Q2 FY27)

    Q2FY27 consolidated revenue: INR 2,735 Cr, up 17.3% YoY (Q2FY26: INR 2,331 Cr) [Pages 11, 33] . Key investor presentation takeaways from Fortis Healthcare Ltd's

  • Dr Agarwal's Hea (Q2 FY27)

    Q2 FY27 revenue from operations: ₹655 Cr, up 31.4% YoY from ₹499 Cr in Q2 FY26 (Page 24) . Key investor presentation takeaways from Dr Agarwals Health Care Ltd'

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Aster DM Quality Care Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Aster DM Quality Care Ltd Q2 FY27 results?

Q2 FY27 revenue: INR 2,829 Cr, up 19% YoY from INR 2,382 Cr in Q2 FY26 (Page 6, 9, 10). Q2 FY27 Operating EBITDA: INR 678 Cr, up 25% YoY from INR 545 Cr (Page 17, 9).

What is Aster DM Quality Care Ltd share price analysis?

Aster DM Quality Care Ltd currently shows a neutral. The stock trades at a P/E of 172.3 with a market cap of ₹62,196 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aster DM Quality Care Ltd planning capital expenditure?

Building a 15,000+ bed healthcare network; adding 4,230 beds to reach 15,070 total beds (Page 18).

Keep Aster DM Quality Care Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.